Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Schaefer-Eckart K, Steffen B, Krause S, Schliemann C, Kaufmann M, Haenel M, Jost E, Crysandt M, Fransecky L, Einsele H, Kraus S, Niemann D, Neubauer A, Seggewiss-Bernhardt R, Scholl S, Klein S, Schmid C, Schaich M, Platzbecker U, Baldus CD, Bornhaeuser M, Serve H, Roellig C, Kramer M, Katelari E, Janssen M, Pabst C, Luft T, Dreger P, Mueller-Tidow C, Sauer T (2022)


Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Pages Range: 3317-3319

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA US

DOI: 10.1182/blood-2022-167677

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Unglaub, J.M., Schlenk, R.F., Hanoun, M., Reinhardt, H.C., Middeke, J.M., Schaefer-Eckart, K.,... Sauer, T. (2022). Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis. In BLOOD (pp. 3317-3319). New Orleans, LA, US: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Unglaub, Julia M., et al. "Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022. 3317-3319.

BibTeX: Download